Amgen arthritis drug shows sustained safety and efficacy
14th Nov 2006, 06:12 GMT
Amgen has said that its product Enbrel has showed improvements in multiple measures of efficacy that were sustained in rheumatoid arthritis patients completing up to nine years of therapy.
Amgen arthritis drug shows sustained safety and efficacy related news:
- Enbrel first biologic with up to 9 years rheumatoid arthritis safety, sustained efficacy data — EurekAlert! - Medicine and Health
- Genentech to Buy Tanox for $919M and Amgen and Wyeth's ENBREL is the First Biologic to Publish Data Showing Safety and Sustained Efficacy — Financial News USA (OTC: FNWU)
- Scots go-ahead for arthritis drug — Scotsman.com News
- Study supports cardiovascular safety of naproxen — Pharmaceutical Business Review Latest News
- Regulator queries safety of anti-flu drug — Guardian Unlimited World Latest
- Amgen Releases Long-Term Enbrel Data — Bio-Technology News from StratCenter.com
- ORENCIA(R) (abatacept) or REMICADE(R)(infliximab) Demonstrated Superior Efficacy to Placebo at Six Months With ORENCIA Demonstrating Both Durable Efficacy and a More Favorable Safety Profile Through 12 Months — PR Newswire: All Releases
- Bristol arthritis drug effective in children: study — Reuters: Health
- Bristol arthritis drug effective in children: study (Reuters) — Yahoo! Health: Health News
- Study Provides Further Support for Cardiovascular Safety of OTC Doses of Naproxen Sodium — Cardiology News from StratCenter.com
Latest news from Pharmaceutical Business Review Latest News:
- Celesio revenues, profits up
- Study supports cardiovascular safety of naproxen
- Cangene chickenpox drug granted orphan status
- Reata brain cancer therapy shows strong activity
- Novartis diabetes drug faces three month delay
- Favrille drug fails secondary goal
- Neurogen commences human testing of obesity drug
- Aeterna prostate cancer drug shows promise
- Isis says new drug effective against cholesterol
- ZymoGenetics, Serono present positive results for atacicept